Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia
Top Cited Papers
Open Access
- 20 December 2012
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 120 (26) , 5173-5180
- https://doi.org/10.1182/blood-2012-07-444042
Abstract
The persistence of minimal residual disease (MRD) during therapy is the strongest adverse prognostic factor in acute lymphoblastic leukemia (ALL). WeKeywords
This publication has 44 references indexed in Scilit:
- Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemiaBlood, 2012
- Clonal evolution in cancerNature, 2012
- High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessmentProceedings of the National Academy of Sciences, 2011
- High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemiaBlood, 2011
- New markers for minimal residual disease detection in acute lymphoblastic leukemiaBlood, 2011
- Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An UpdateJournal of Clinical Oncology, 2011
- Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemiaBlood, 2010
- Treating Childhood Acute Lymphoblastic Leukemia without Cranial IrradiationNew England Journal of Medicine, 2009
- Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group studyBlood, 2008
- Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01Blood, 2007